Cytarabine nanotherapeutics with increased stability and enhanced lymphoma uptake for tailored highly effective therapy of mantle cell lymphoma
Jazyk angličtina Země Anglie, Velká Británie Médium print-electronic
Typ dokumentu časopisecké články, práce podpořená grantem
PubMed
33186784
DOI
10.1016/j.actbio.2020.11.014
PII: S1742-7061(20)30657-7
Knihovny.cz E-zdroje
- Klíčová slova
- Cytarabine, Drug delivery, HPMA copolymer, Mantle cell lymphoma, Nanotherapeutics, Patient-derived xenograft (PDX),
- MeSH
- cytarabin farmakologie MeSH
- dospělí MeSH
- lidé MeSH
- lokální recidiva nádoru MeSH
- lymfom z plášťových buněk * farmakoterapie MeSH
- protokoly antitumorózní kombinované chemoterapie MeSH
- rituximab terapeutické užití MeSH
- výsledek terapie MeSH
- Check Tag
- dospělí MeSH
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- Názvy látek
- cytarabin MeSH
- rituximab MeSH
Mantle cell lymphoma (MCL) is a rare subtype of B-cell non-Hodgkin lymphoma (B-NHL) with chronically relapsing clinical course. Implementation of cytarabine (araC) into induction and salvage regimen became standard of care for majority of MCL patients. In this study, tailored N-(2-hydroxypropyl)methacrylamide (HPMA)-based polymer nanotherapeutics containing covalently bound araC (araC co-polymers) were designed, synthesized and evaluated for their anti-lymphoma efficacy in vivo using a panel of six patient-derived lymphoma xenografts (PDX) derived from newly diagnosed and relapsed / refractory (R/R) MCL. While free araC led to temporary inhibition of growth of MCL tumors, araC co-polymers induced long-term disappearance of the engrafted lymphomas with no observed toxicity even in the case of PDX models derived from patients, who relapsed after high-dose araC-based treatments. The results provide sound preclinical rationale for the use of HPMA-based araC co-polymers in induction, salvage or palliative therapy of MCL patients.
Citace poskytuje Crossref.org
